

Pembrolizumab versus brentuximab vedotin in relapse lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, phase 3 study

Lancet Oncology, The
22, 512-524

DOI: [10.1016/s1470-2045\(21\)00005-x](https://doi.org/10.1016/s1470-2045(21)00005-x)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Immune Checkpoint Inhibitors in Special Populations. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110365. | 1.9 | 4 |
| 2 | Relapsed or refractory classical Hodgkin lymphoma: which immunotherapy, and when?. <i>Lancet Oncology</i> , The, 2021, 22, 417-419. | 10.7 | 4 |
| 3 | PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma. <i>Cells</i> , 2021, 10, 1152. | 4.1 | 12 |
| 4 | Successful pregnancy and fetal outcome following previous treatment with pembrolizumab for relapsed Hodgkin's lymphoma. <i>Cancer Reports</i> , 2021, , e1432. | 1.4 | 5 |
| 5 | Pembrolizumab for relapsed or refractory Hodgkin lymphoma. <i>Lancet Oncology</i> , The, 2021, 22, e234. | 10.7 | 0 |
| 6 | Biomodulatory Treatment Regimen, MEPED, Rescues Relapsed and Refractory Classic Hodgkin's Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 599561. | 3.5 | 11 |
| 7 | Pembrolizumab for relapsed or refractory Hodgkin lymphoma – Author's reply. <i>Lancet Oncology</i> , The, 2021, 22, e235. | 10.7 | 0 |
| 8 | Immune checkpoint inhibitors in lymphoma: challenges and opportunities. <i>Annals of Translational Medicine</i> , 2021, 9, 1037-1037. | 1.7 | 30 |
| 9 | Outcomes Related to FDG-PET-CT Response in Patients With Hodgkin Lymphoma Treated With Brentuximab-Vedotin at Relapse or Consolidation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e929-e937. | 0.4 | 4 |
| 10 | New approaches to managing relapsed/refractory Hodgkin lymphoma: the role of checkpoint inhibitors and beyond. <i>Expert Review of Hematology</i> , 2021, 14, 741-750. | 2.2 | 0 |
| 11 | Cardiac complications associated with hematopoietic stem-cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2637-2643. | 2.4 | 11 |
| 12 | FDG-PET/CT for the Management of Post-Chemotherapy Residual Mass in Hodgkin lymphoma. <i>Cancers</i> , 2021, 13, 3952. | 3.7 | 4 |
| 13 | Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients. <i>Journal of Chemotherapy</i> , 2022, 34, 190-198. | 1.5 | 7 |
| 14 | Optimizing Second-Line Therapy for Hodgkin Lymphoma: A Work in Progress. <i>Journal of Clinical Oncology</i> , 2021, 39, 3097-3103. | 1.6 | 4 |
| 15 | Advances in immune therapies in hematological malignancies. <i>Journal of Internal Medicine</i> , 2022, 292, 205-220. | 6.0 | 5 |
| 16 | Programmed cell death protein blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation in an adolescent patient. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29390. | 1.5 | 2 |
| 17 | Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis. <i>Leukemia</i> , 2022, 36, 772-780. | 7.2 | 6 |
| 18 | Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma. <i>Blood Advances</i> , 2022, 6, 590-599. | 5.2 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Is the Scope of Costs Considered in Budget Impact Analyses for Anticancer Drugs Rational? A Systematic Review and Comparative Study. <i>Frontiers in Public Health</i> , 2021, 9, 777199. | 2.7 | 2 |
| 20 | Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis. <i>Life</i> , 2021, 11, 1277. | 2.4 | 4 |
| 21 | An unusual case of microsatellite instabilityâ€“high/deficient mismatch repair (MSI-H/dMMR) diffuse large B-cell lymphoma revealed by targeted gene sequencing. <i>Journal of Pathology and Translational Medicine</i> , 2022, 56, 92-96. | 1.1 | 3 |
| 22 | Hodgkin Lymphoma: Recent Progress in Overall Management. , 0, , 83-116. | | 0 |
| 23 | The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 792691. | 4.8 | 39 |
| 24 | Current salvage therapies in Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1267-1280. | 1.3 | 5 |
| 25 | Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas. <i>Cancers</i> , 2022, 14, 626. | 3.7 | 11 |
| 26 | The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma. <i>Journal of Personalized Medicine</i> , 2022, 12, 197. | 2.5 | 4 |
| 27 | The Efficacy of Brentuximab Vedotin in Relapsed/Refractory Classical Hodgkinâ€™s Lymphoma and Quality of Life: Results of a Multi-Center Observational Prospective Study in the Context of Real Clinical Practice. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2022, 15, 42-53. | 0.4 | 0 |
| 28 | Immunomodulatory Properties of Immune Checkpoint Inhibitorsâ€™”More than Boosting T-Cell Responses?. <i>Cancers</i> , 2022, 14, 1710. | 3.7 | 13 |
| 29 | Autologous Stem Cell Transplantation in Hodgkin Lymphomaâ€™”Latest Advances in the Era of Novel Therapies. <i>Cancers</i> , 2022, 14, 1738. | 3.7 | 5 |
| 30 | Lymphoma: New Diagnosis and Current Treatment Strategies. <i>Journal of Clinical Medicine</i> , 2022, 11, 1701. | 2.4 | 1 |
| 31 | Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. <i>Cell Communication and Signaling</i> , 2022, 20, 44. | 6.5 | 109 |
| 32 | NCCN Guidelinesâ€™ Insights: Hodgkin Lymphoma, Version 2.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 322-334. | 4.9 | 35 |
| 33 | An evaluation of pembrolizumab for classical Hodgkin lymphoma. <i>Expert Review of Hematology</i> , 2022, 15, 285-293. | 2.2 | 1 |
| 34 | Did brentuximab vedotinâ€™s rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results?. <i>Haematologica</i> , 2021, , . | 3.5 | 0 |
| 35 | Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy. <i>Cancers</i> , 2021, 13, 6125. | 3.7 | 11 |
| 36 | How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 240-246. | 2.5 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 803410. | 4.8 | 25 |
| 38 | Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 862084. | 4.8 | 18 |
| 39 | HÄmatologie und Onkologie. , 2022, , 229-289. | | 0 |
| 40 | Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma. <i>Leukemia Research Reports</i> , 2022, 17, 100319. | 0.4 | 0 |
| 41 | Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, . | 3.5 | 12 |
| 44 | Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway. <i>Current Oncology Reports</i> , 2022, 24, 1477-1488. | 4.0 | 1 |
| 45 | Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkinâ€™s Lymphoma. <i>Cancers</i> , 2022, 14, 2936. | 3.7 | 4 |
| 46 | PD-1 Blockade After Avelumab in Relapsed/Refractory Classical Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e893-e897. | 0.4 | 2 |
| 47 | PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas. <i>Biomedicines</i> , 2022, 10, 1587. | 3.2 | 6 |
| 48 | Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201). <i>Frontiers in Oncology</i> , 0, 12, . | 2.8 | 6 |
| 49 | Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review. <i>Frontiers in Oncology</i> , 0, 12, . | 2.8 | 3 |
| 50 | Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory Classical Hodgkinâ€™s Lymphoma: So Many Options, How to Choose?. <i>Cancers</i> , 2022, 14, 3526. | 3.7 | 2 |
| 51 | Adverse Renal Effects of Anticancer Immunotherapy: A Review. <i>Cancers</i> , 2022, 14, 4086. | 3.7 | 3 |
| 53 | The outcome of older adults with classic Hodgkin lymphoma in British Columbia. <i>Blood Advances</i> , 2022, 6, 5924-5932. | 5.2 | 3 |
| 54 | The role of B cells in the development, progression, and treatment of lymphomas and solid tumors. <i>Advances in Immunology</i> , 2022, , 71-117. | 2.2 | 0 |
| 55 | Hodgkin lymphoma: 2023 update on diagnosis, riskâ€™stratification, and management. <i>American Journal of Hematology</i> , 2022, 97, 1478-1488. | 4.1 | 19 |
| 56 | Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer. , 2022, 10, e005128. | | 4 |
| 57 | CD25-targeted antibodyâ€™drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma. <i>Investigational New Drugs</i> , 2022, 40, 1333-1341. | 2.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 58 | Infectious Complications of Targeted Therapies in Children with Leukemias and Lymphomas. <i>Cancers</i> , 2022, 14, 5022. | 3.7 | 3 |
| 59 | Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma. <i>Experimental Hematology and Oncology</i> , 2022, 11, . | 5.0 | 9 |
| 60 | Immune Checkpoint Inhibitors in Hodgkin Lymphoma and Non-Hodgkin Lymphoma. , 0, , . | | 0 |
| 61 | Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 6574. | 2.4 | 4 |
| 62 | Clinical Dilemmas in the Treatment of Elderly Patients Suffering from Hodgkin Lymphoma: A Review. <i>Biomedicines</i> , 2022, 10, 2917. | 3.2 | 0 |
| 63 | Incidence rate and treatment strategy of immune checkpoint inhibitor mediated hepatotoxicity: A systematic review. , 2023, 1, 46-55. | | 1 |
| 64 | Therapeutic Antibodies in Cancer Treatment in the UK. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14589. | 4.1 | 1 |
| 65 | Promising drugs and treatment options for pediatric and adolescent patients with Hodgkin lymphoma. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, . | 3.7 | 2 |
| 66 | Anti-PD1 Consolidation in Patients with Hodgkin Lymphoma at High Risk of Relapse after Autologous Stem Cell Transplantation: A Multicenter Real-Life Study. <i>Cancers</i> , 2022, 14, 5846. | 3.7 | 2 |
| 67 | Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 763-794. | 0.8 | 8 |
| 68 | Hodgkin lymphomaâ€”how much therapy do we need?. <i>Memo - Magazine of European Medical Oncology</i> , 0, , . | 0.5 | 1 |
| 69 | Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma in Switzerland, 20 years of experience: 2001â€”2020. <i>EJHaem</i> , 0, , . | 1.0 | 0 |
| 70 | Anti-CD30 antibodyâ€”drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives. <i>Annals of Hematology</i> , 2023, 102, 13-29. | 1.8 | 7 |
| 71 | Clinical characteristics of Australian treatmentâ€”naïve patients with classical Hodgkin Lymphoma from the Lymphoma and Related Diseases Registry. <i>European Journal of Haematology</i> , 0, , . | 2.2 | 0 |
| 72 | Checkpoint inhibitorâ€”based salvage regimens prior to autologous stem cell transplant improve eventâ€”free survival in relapsed/refractory classic Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2023, 98, 464-471. | 4.1 | 4 |
| 73 | Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. <i>Cancer Cell</i> , 2023, 41, 210-225.e5. | 16.8 | 32 |
| 74 | Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches. <i>Experimental Hematology and Oncology</i> , 2022, 11, . | 5.0 | 4 |
| 75 | The Non-Hodgkin Lymphoma Treatment and Side Effects: A Systematic Review and Meta-Analysis. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2023, 18, . | 1.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 76 | PD-L1: expression regulation. <i>Blood Science</i> , 2023, 5, 77-91. | 0.9 | 5 |
| 77 | Immunotherapy for Hodgkin lymphoma: From monoclonal antibodies to chimeric antigen receptor T-cell therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 182, 103923. | 4.4 | 1 |
| 78 | Checkpoint Blockade in Hematologic Malignancies. , 2022, , 1-42. | | 0 |
| 79 | A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma. <i>Cancers</i> , 2023, 15, 1437. | 3.7 | 3 |
| 80 | Current Treatment Options and the Role of Functional Status Assessment in Classical Hodgkin Lymphoma in Older Adults: A Review. <i>Cancers</i> , 2023, 15, 1515. | 3.7 | 0 |
| 81 | Advances and Clinical Outcomes in Hodgkin Lymphoma in the Era of Novel Therapies. <i>Journal of Clinical Medicine</i> , 2023, 12, 1928. | 2.4 | 0 |
| 82 | Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy. <i>World Journal of Clinical Cases</i> , 0, 11, 1458-1466. | 0.8 | 0 |
| 83 | Radiomics-guided checkpoint inhibitor immunotherapy for precision medicine in cancer: A review for clinicians. <i>Frontiers in Immunology</i> , 0, 14, . | 4.8 | 1 |
| 84 | Advances in the treatment of Hodgkin lymphoma: Current and future approaches. <i>Frontiers in Oncology</i> , 0, 13, . | 2.8 | 4 |
| 85 | Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: a systematic review and meta-analysis of 20 prospective studies. <i>Hematology</i> , 2023, 28, . | 1.5 | 4 |
| 86 | Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma. <i>JAMA Oncology</i> , 2023, 9, 683. | 7.1 | 11 |
| 87 | Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant. <i>HemaSphere</i> , 2023, 7, e869. | 2.7 | 1 |
| 88 | Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trial. <i>Leukemia and Lymphoma</i> , 2023, 64, 1017-1025. | 1.3 | 3 |
| 89 | Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma. <i>Cancer Medicine</i> , 2023, 12, 10351-10362. | 2.8 | 1 |
| 90 | Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 14, . | 3.5 | 2 |
| 91 | Pembrolizumab-induced optic neuropathy â€“ a case report. <i>Frontiers in Immunology</i> , 0, 14, . | 4.8 | 2 |
| 92 | <sc>CD30</sc> as a therapeutic target in adult haematological malignancies: Where are we now?. <i>British Journal of Haematology</i> , 2023, 201, 1033-1046. | 2.5 | 3 |
| 93 | Successful restoration of checkpoint inhibitors efficacy after allogeneic hematopoietic cell transplant for classic Hodgkin lymphoma patients. <i>Seminars in Oncology</i> , 2023, 50, 76-85. | 2.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 94 | The clinical application of immuno-therapeutics. , 2024, , 237-288.e7. | | 0 |
| 95 | Antibodyâ€“drug conjugates come of age in oncology. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 641-661. | 46.4 | 82 |
| 96 | Classical Hodgkin Lymphoma: From Past to Futureâ€”A Comprehensive Review of Pathophysiology and Therapeutic Advances. <i>International Journal of Molecular Sciences</i> , 2023, 24, 10095. | 4.1 | 1 |
| 97 | Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. <i>Blood</i> , 2023, 142, 878-886. | 1.4 | 10 |
| 98 | A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma. <i>Blood</i> , 2023, 142, 621-628. | 1.4 | 4 |
| 99 | SOHO State of the Art Updates and Next Questions From Biology to Therapy: Progress in Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, , . | 0.4 | 0 |
| 100 | Efficacy of Immune Checkpoint Blockade and Biomarkers of Response in Lymphoma: A Narrative Review. <i>Biomedicines</i> , 2023, 11, 1720. | 3.2 | 2 |
| 101 | A unique expression pattern of <sc><i>LAG3</i></sc> distinct from that of other immune checkpoints in diffuse large Bâ€“cell lymphoma. <i>Cancer Medicine</i> , 2023, 12, 16359-16369. | 2.8 | 1 |
| 102 | Clinical applications of circulating tumor DNA in Hodgkin lymphoma. <i>Seminars in Hematology</i> , 2023, , . | 3.4 | 0 |
| 103 | Novel Drugs and Radiotherapy in Relapsed Lymphomas: Abscopal Response and Beyond. <i>Cancers</i> , 2023, 15, 2751. | 3.7 | 0 |
| 104 | Tackling the dysregulated immune-checkpoints in classical Hodgkin lymphoma: bidirectional regulations between the microenvironment and Hodgkin/Reed-Sternberg cells. <i>Frontiers in Oncology</i> , 0, 13, . | 2.8 | 2 |
| 105 | PET Project: Introducing PD-1 and ctDNA into Frontline Therapy for Early-stage Classic Hodgkin Lymphoma. , 2023, 20, . | | 0 |
| 106 | T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions. <i>Frontiers in Oncology</i> , 0, 13, . | 2.8 | 0 |
| 107 | A Review of Hodgkin Lymphoma in the Era of Checkpoint Inhibitors. <i>Cureus</i> , 2023, , . | 0.5 | 0 |
| 108 | Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6). <i>Targeted Oncology</i> , 0, , . | 3.6 | 0 |
| 109 | Two Older Hematological Malignancy Patients for Whom Nutrition Rehabilitation Was Effective Against Global Leadership Initiative on Malnutrition-Defined Malnutrition and Sarcopenia. <i>Cureus</i> , 2023, , . | 0.5 | 1 |
| 110 | The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma. <i>Experimental Hematology and Oncology</i> , 2023, 12, . | 5.0 | 4 |
| 111 | Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, . | 17.1 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 112 | Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 13187. | 4.1 | 3 |
| 113 | Therapeutic Antibodies in Medicine. <i>Molecules</i> , 2023, 28, 6438. | 3.8 | 3 |
| 114 | Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy. <i>Cancers</i> , 2023, 15, 4509. | 3.7 | 1 |
| 115 | Overall survival of cHL patients who progress after autologous stem cell transplant: results in novel agent era.. <i>Blood Advances</i> , 0, , . | 5.2 | 0 |
| 116 | Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study. <i>Blood Advances</i> , 2023, 7, 6266-6274. | 5.2 | 3 |
| 117 | Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress. <i>Cancers</i> , 2023, 15, 5060. | 3.7 | 0 |
| 118 | Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, . | 17.1 | 0 |
| 119 | Disparity in survival benefits of pembrolizumab between Asian and non-Asian patients with advanced cancers: A systematic review and meta-regression analysis. <i>Cancer Medicine</i> , 2023, 12, 20035-20051. | 2.8 | 0 |
| 120 | Effectiveness and Safety of Pembrolizumab in Recurrent and Relapsed Classic Hodgkin Lymphoma: A Systematic Review. <i>Cureus</i> , 2023, , . | 0.5 | 0 |
| 121 | Hodgkin Lymphoma: A disease shaped by the tumor micro- and macroenvironment. <i>Best Practice and Research in Clinical Haematology</i> , 2023, 36, 101514. | 1.7 | 0 |
| 122 | Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis. , 2023, 2, 346-375. | | 0 |
| 123 | Checkpoint inhibition in hematologic malignancies. <i>Frontiers in Oncology</i> , 0, 13, . | 2.8 | 0 |
| 124 | APR-246 increases tumor antigenicity independent of p53. <i>Life Science Alliance</i> , 2024, 7, e202301999. | 2.8 | 0 |
| 125 | Sequencing novel agents in the treatment of classical Hodgkin lymphoma. <i>Expert Review of Hematology</i> , 2023, 16, 991-1015. | 2.2 | 0 |
| 126 | Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations. <i>Translational Oncology</i> , 2024, 40, 101851. | 3.7 | 1 |
| 127 | Antibody based therapies in Hodgkin lymphoma. <i>Cancer Treatment Reviews</i> , 2024, 122, 102647. | 7.7 | 0 |
| 128 | The role of radiotherapy in patients with refractory Hodgkin's lymphoma after treatment with brentuximab vedotin and/or immune checkpoint inhibitors. <i>Journal of the National Cancer Center</i> , 2023, , . | 7.4 | 0 |
| 129 | Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy. <i>Blood</i> , 2024, 143, 786-795. | 1.4 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 130 | All-cause and immune checkpoint inhibitor-associated acute kidney injury in immune checkpoint inhibitor users: a meta-analysis of occurrence rate, risk factors and mortality. CKJ: Clinical Kidney Journal, 2024, 17, . | 2.9 | 1 |
| 131 | Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in brazil: Balancing efficacy, safety, and tolerability. Oncotarget, 2023, 14, 977-994. | 1.8 | 0 |
| 132 | Checkpoint Immunotherapy in Pediatric Oncology: Will We Say Checkmate Soon?. Vaccines, 2023, 11, 1843. | 4.4 | 0 |
| 133 | High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategies. Leukemia and Lymphoma, 2024, 65, 460-471. | 1.3 | 1 |
| 134 | Prognostic Impact of Serum Î²2-Microglobulin Levels in Hodgkin Lymphoma Treated with ABVD or Equivalent Regimens: A Comprehensive Analysis of 915 Patients. Cancers, 2024, 16, 238. | 3.7 | 0 |
| 135 | Immune checkpoint blockade in hematological malignancies: current state and future potential. Frontiers in Oncology, 0, 14, . | 2.8 | 0 |
| 136 | Radiotherapy for Advanced Hodgkin Lymphoma with Initial Bulk: A Combined Analysis of Two Randomized Trials. Advances in Radiation Oncology, 2024, 9, 101450. | 1.2 | 0 |
| 137 | Diagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review. Diagnostics, 2024, 14, 336. | 2.6 | 0 |
| 139 | How Early Can Checkpoint Inhibitors Induce a Complete Metabolic Response in Chemorefractory Hodgkin Lymphoma?. Clinical Nuclear Medicine, 2024, 49, 327-329. | 1.3 | 0 |
| 140 | Hodgkin-Lymphom. , 2024, , 475-490. | | 0 |
| 142 | Aâ€‰+â€‰AVD for Treatment of Hodgkin Lymphoma Variant of Richterâ€™s Transformation. Case Reports in Hematology, 2024, 2024, 1-8. | 0.4 | 0 |
| 143 | Association between sex and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. Immunotherapy, 2024, 16, 481-495. | 2.0 | 0 |
| 144 | Remission of relapsed/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem cell transplantation: a case report. Frontiers in Immunology, 0, 15, . | 4.8 | 0 |